# Cabozantinib Dose Skipping as an Alternative to Dose Reductions

> **NCT07077161** · PHASE2 · RECRUITING · sponsor: **dr. Tom van der Hulle** · enrollment: 34 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT07077161
- **Lead sponsor:** dr. Tom van der Hulle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077161, "Cabozantinib Dose Skipping as an Alternative to Dose Reductions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07077161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*